Pre-CRT SUV |
HR |
95% CI |
p-value |
<8 vs >8 |
2.062 |
0.597 – 7.128 |
0.253 |
<10 vs >10 |
1.285 |
0.482 – 3.425 |
0.617 |
<12 vs >12 |
0.933 |
0.369 – 2.357 |
0.883 |
<14 vs >14 |
0.625 |
0.223 – 1.760 |
0.375 |
<16 vs >16 |
0.845 |
0.276 – 2.580 |
0.767 |
<18 vs >18 |
1.037 |
0.299 – 3.956 |
0.955 |
|
|
|
|
% SUV Change |
HR |
95% CI |
p-value |
<30% vs >30% |
1.338 |
0.386 – 4.637 |
0.647 |
<40% vs >40% |
0.976 |
0.347 - 2.742 |
0.963 |
<50% vs >50% |
0.281 |
0.105 – 0.754 |
0.012 |
<60% vs >60% |
0.285 |
0.100 – 0.809 |
0.018 |
<70% vs >70% |
0.271 |
0.060 – 1.221 |
0.089 |
|
|
|
|
Post-CRT SUV |
HR |
95% CI |
p-value |
<3 vs >3* |
- |
- |
- |
<4 vs >4 |
6.36 |
1.439 – 28.11 |
0.015 |
<5 vs >5 |
3.248 |
1.174 – 8.988 |
0.023 |
<6 vs >6 |
2.76 |
1.026 – 7.430 |
0.044 |
<7 vs >7 |
4.833 |
1.744 – 13.394 |
0.002 |
*- hazard ratio for 3 could not be calculated since there were no deaths in patients
with Post-CRT SUV <3; HR – hazard ratio; CI – confidence interval; CRT –
chemoradiotherapy; SUV – standard uptake value |